Kinpeygo Ευρωπαϊκή Ένωση - Φινλανδικά - EMA (European Medicines Agency)

kinpeygo

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - ripulilääkkeet, suoliston antiinflammatory / antiinfective agents - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Budesonid Medical Valley 3 mg säädellysti vapauttava kapseli, kova Φινλανδία - Φινλανδικά - Fimea (Suomen lääkevirasto)

budesonid medical valley 3 mg säädellysti vapauttava kapseli, kova

medical valley invest ab - budesonide - säädellysti vapauttava kapseli, kova - 3 mg - budesonidi

Budenofalk 4 mg peräpuikko Φινλανδία - Φινλανδικά - Fimea (Suomen lääkevirasto)

budenofalk 4 mg peräpuikko

dr. falk pharma gmbh - budesonide - peräpuikko - 4 mg - budesonidi

Riltrava Aerosphere Ευρωπαϊκή Ένωση - Φινλανδικά - EMA (European Medicines Agency)

riltrava aerosphere

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

BUDERATIO 0.25 mg/ml sumutinsuspensio Φινλανδία - Φινλανδικά - Fimea (Suomen lääkevirasto)

buderatio 0.25 mg/ml sumutinsuspensio

teva pharma b.v. - budesonidum - sumutinsuspensio - 0.25 mg/ml - budesonidi

Trixeo Aerosphere Ευρωπαϊκή Ένωση - Φινλανδικά - EMA (European Medicines Agency)

trixeo aerosphere

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.